FDA panel review looms for controversial libido drug

The first time researchers studied flibanserin, they thought they had a potential new depression therapy on their hands. That approach failed. But now Boehringer Ingelheim is preparing to make the case to a panel of FDA experts that the drug should be approved to boost women's libido, seeking an approval for a 'pink Viagra' that could earn up to $2 billion a year. The agency's views have yet to be heard, but there's already plenty of debate in women's health circles about the prospects of a new...